Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine and Lidocaine Infusion in Hepatectomy
NCT06778460Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine and Lidocaine Hydrochloride Injection, without epinephrine in chronic post-surgical pain (CPSP) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: The incidence of chronic pain at 3 months postoperatively. Started May 2023; status: recruiting.
02
Drugs
esketamineLidocaine Hydrochloride Injection, without epinephrine
03
Conditions
chronic post-surgical pain (CPSP)
Beyond the preview
Go deeper on NCT06778460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778460.